

JAGADISHWAR

PHARMACEUTICAL WORKS LIMITED

CIN : L24232AS1987PLC002803

Regd. Off.: 205, Haribol Roy Market, 2nd Floor, A.T.Road, Guwahati -781001

Corp. Off.: 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Website: jagadishwarpharma.com

E_mail ID: jpw ltd@yahoo.com

Phone No.: +91 9163513015

Date: May 29, 2025

To,
The Deputy Gen. Manager,
Metropolitan Stock Exchange of India Ltd. (MSEI),
205(A), 2nd Floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West),
Mumbai – 400 070

Dear Sir / Madam,

Sub: Outcome of Board Meeting of Jagadishwar Pharmaceutical Works Limited held on May 29, 2025.

Ref: Regulation 33 (3) of SEBI (Listing Obligation and Disclosures Requirements) Regulations 2015

With reference to the above captioned subject, outcome of the meeting of the Board of Directors of Jagadishwar Pharmaceutical Works Limited which was held today at 03.00 p.m. and concluded at 03.30 p.m. is as follows:

Approved Audited Standalone Financial Results of the Company for the quarter and year ended on March 31, 2025.

Find enclosed herewith a copy of Audited Standalone Financial Results along with Auditors Report pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.


The Report of Auditors is with unmodified opinion with respect to the Audited Standalone Financial Results of the Company for the year ended March 31, 2025.


You are requested to take note of the same.

Thanking You,

Yours Faithfully,

For Jagadishwar Pharmaceutical Works Limited


Swapan Sarkar
Director
DIN: 05149442



Encl: As above



Independent Auditor's Report (Unmodified Opinion) on Audited standalone Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF JAGADISHWAR PHARMACEUTICAL WORKS LIMITED

Report on the audit of the Standalone Financial Results Opinion

We have audited the accompanying standalone quarterly financial results of Jagadishwar Pharmaceutical Works Limited (Name of the company) (the company) for the quarter ended 31st March, 2025 (date of the quarter end) and the year to date results for the period from April 01, 2024 to March 31, 2025, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information for the quarter ended 31st March, 2025 as well as the year to date results for the period from April 01, 2024 to March 31, 2025.


Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our opinion is not modified in respect of this matter.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net **loss** and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.





In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.


As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Place: Kolkata
Date: 29.05.2025



For **Rajesh U Shah & Associates**
Chartered Accountants


Rajesh Shah
Proprietor

Membership Number: 056550

Firm Regn. No.: 327799E

UDIN: 25056550BM0MAH9170

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)


Regd. Office: 205, Haribol Roy Market, A.T.Road, 2nd Floor, Near Saraf Building, Guwahati - 781 001

Corp. Office : 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email ID: jpwltid@yahoo.com, **Website:** jagadishwarpharma.com, **Tel:** +91 9163513015

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2025 (Audited)	31-12-2024 (Unaudited)	31-03-2024 (Audited)	31-03-2005 (Audited)	31-03-2024 (Audited)
(Rs. in Lakhs)						
1	Income From Operations					
	(a) Net Sales / Income from Operations	-	-	-	-	-
	(b) Other Operating Income	6.325	6.568	7.180	25.080	29.520
	Total Income from Operations	6.325	6.568	7.180	25.080	29.520
2	Expenses					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Purchase of stock-in-trade	5.075	7.250	-	12.325	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	5.075	7.250	-	12.325	-
	(d) Employee benefits expense	7.012	7.756	7.304	35.128	30.861
	(e) Depreciation and amortisation expense	0.166	-	0.057	0.166	0.057
	(f) Finance Cost	-	-	-	-	-
	(g) Other expenses	2.217	0.931	0.983	8.674	9.930
	Total Expenses	9.395	8.688	8.344	43.967	40.848
3	Profit / (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(3.070)	(2.120)	(1.164)	(18.887)	(11.328)
4	Other Income	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)	(3.070)	(2.120)	(1.164)	(18.887)	(11.328)
6	Finance Costs	-	-	-	-	-
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(3.070)	(2.120)	(1.164)	(18.887)	(11.328)
8	Exceptional Items	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7-8)	(3.070)	(2.120)	(1.164)	(18.887)	(11.328)
10	Tax Expense	-	-	-	-	-
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	(3.070)	(2.120)	(1.164)	(18.887)	(11.328)
12	Extraordinary item (net of tax Rs. Nil Lakhs)	-	-	-	-	-
13	Net Profit / (Loss) for the period (11-12)	(3.070)	(2.120)	(1.164)	(18.887)	(11.328)
14	Share of Profit / (loss) of associates	-	-	-	-	-
15	Minority Interest	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13-14-15)	(3.070)	(2.120)	(1.164)	(18.887)	(11.328)
17	Other Comprehensive Income	12.271	-	14.876	12.271	14.876
18	Total Comprehensive Income	9.201	(2.120)	13.711	(6.617)	3.548
19	Paid-up Equity Share Capital (Face Value of Rs.10/- per Share)	2,970.020	2,970.020	2,970.020	2,970.020	2,970.020
20	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	138.953	135.405
21.i	Earnings Per Share (before extraordinary items) of Rs. 10/- each) (not annualised)					
	(a) Basic	-	-	-	-	-
	(b) Diluted	-	-	-	-	-
21.ii	Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)					
	(a) Basic	-	-	-	-	-
	(b) Diluted	-	-	-	-	-



Notes:	
1	The above audited standalone financial results for the quarter and year ended 31 March 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th May, 2025.
2	Figures for the quarter ended 31 March, 2025 and corresponding quarter ended in the previous year as reported in these standalone financial results are the balancing figures in respect of the full financial year and the published year-to-date figures up to the end of third quarter of the relevant financial year. Also the figures upto the end of third quarter had only been reviewed and not subjected to audit.
3	The standalone financial results of the Company for the quarter and year ended 31st March, 2025 have been audited by the Statutory Auditors.
4	The Statutory Auditors of the Company have conducted audit of these financial results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and have issued Audit Report with unmodified opinion
5	Previous period/Year figures have been regrouped/reclassified to make them comparable with those of current period/year.
	Place: Kolkata Dated: 29th May, 2025 For Jagadishwar Pharmaceutical Works Limited  Swapan Sarkar Swapan Sarkar Director (DIN : 05149442)

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

AUDITED STATEMENTS OF ASSETS AND LIABILITIES				(Rs. in Lakhs)
Sr. No.	Particulars	As at 31-03-2025	As at 31-03-2024	
		Audited	Audited	
A)	Assets			
1)	Non Current Assets			
	a) Fixed Assets	0.10	0.26	
	b) Goodwill on consolidation	-	-	
	c) Non-current investments	1,336.50	1,324.23	
	d) Long term loans and advances	3.83	4.28	
	e) Other Non current assets	-	-	
	Sub Total-Non Current Assets	1,340.43	1,328.78	
2)	Current Assets			
	a) Current Investments	-	-	
	b) Inventories	445.38	433.06	
	c) Trade receivables	-	-	
	d) Cash and Cash equivalents	2.25	7.16	
	e) Short term loans and advances	290.69	326.46	
	f) Other current assets	1,026.07	1,016.07	
	Sub Total-Total Current Assets	1,764.39	1,782.75	
	Total Assets	3,104.82	3,111.52	
B)	Equity and Liabilities			
1)	Shareholders Fund			
	a) Share Capital	2,970.02	2,970.02	
	b) Reserves and Surplus	132.34	138.95	
	Sub Total- Shareholders Fund	3,102.36	3,108.97	
2)	Non-Current Liabilities			
	a) Long term borrowings	-	-	
	b) Other Long term Liabilities	-	-	
	c) Long term provisions	-	-	
	Sub Total- Non Current Liabilities	-	-	
3)	Current Liabilities			
	a) Short term borrowings	-	-	
	b) Trade payables	-	-	
	c) Other current Liabilities	2.47	2.55	
	d) Other short term provisions	-	-	
	Sub Total-Current Liabilities	2.47	2.55	
	Total -Equity and Liabilities	3,104.82	3,111.52	

For Jagadishwar Pharmaceutical Works Limited



Swapan Sarkar
Director
(DIN : 05149442)

Place: Kolkata
Dated: 29th May, 2025

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2025

(Rs. in Lakhs)

PARTICULARS		As at 31 March, 2025	As at 31 March, 2024
A. <u>Cash Flow from Operating Activities</u>			
Net Profit/(Loss) before tax		(18.89)	(11.33)
Add : Depreciation		0.17	0.06
Add: Interest Expenses		-	-
Add: Loss on sale of Fixed Asset		-	-
Less :Interest Income		(25.08)	(29.52)
Operating Profit before Working Capital Changes		(43.80)	(40.80)
Adjustment for :			
Non Current Financial Assets		-	-
Other Non Current Assets		-	-
Inventories		(12.33)	-
Trade Receivable		-	-
Other Current Assets		25.77	4.47
Loans and Advances		-	-
Trade payable and other Liabilities		-	-
Other Financial Liabilities		-	-
Other Current Liabilities		(0.08)	2.45
Net Cash inflow from/(outflow) from operating activities		(30.43)	(33.89)
B. <u>Cash Flow from Investing Activities</u>			
Sale Proceeds from Fixed Assets		-	-
Interest Received		25.08	29.52
Fixed Assets Purchase		-	(0.32)
Income Tax Paid		0.45	(0.76)
Net Cash inflow from/(outflow) from Investing Activities		25.53	28.44
C. <u>Cash Flow from Financing Activities</u>			
Proceeds from Borrowing		-	-
Interest paid		-	-
Dividend Paid		-	-
Net Cash inflow from/(outflow) from Financing Activities		-	-
Net Increase /(decrease) in cash and Cash Equivalents		(4.91)	(5.44)
Opening Cash and Cash Equivalents			
Cash in Hand		5.49	9.45
Bank balances		1.66	3.14
Total		7.15	12.59
Closing Cash and Cash Equivalents			
Cash in Hand		0.35	5.49
Bank balances		1.89	1.66
Total		2.24	7.15

For Jagadishwar Pharmaceutical Works Limited

Swapan Sarkar
Director
DIN : 05149442



Place: Kolkata
Dated: 29th May, 2025

JAGADISHWAR

PHARMACEUTICAL WORKS LIMITED

CIN : L24232AS1987PLC002803

Regd. Off.: 205, Haribol Roy Market, 2nd Floor, A.T.Road, Guwahati -781001

Corp. Off.: 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Website: jagadishwarpharma.com

E_mail ID: jpwlttd@yahoo.com

Phone No.: +91 9163513015

Date: 29/05/2025

To,
The Deputy Gen. Manager,
Metropolitan Stock Exchange of India Ltd.
205(A), 2nd Floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West),
Mumbai – 400 070

Subject: Declaration confirming issuance of Audited Reports with 'Unmodified Opinion' on Standalone Financial Statement of Jagadishwar Pharmaceutical Works Limited the Company for the financial year ended 31st March, 2025.

Pursuance to regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements Regulation, 2015 (LODR). I, Swapan Sarkar, Director of the Company do hereby declare and confirm that Statutory Auditors of the Company i.e. M/s. Rajesh U Shah & Associates, Chartered Accountants have issued their Audit Report with Unmodified Opinion on the Standalone Financial Result Company for the financial year ended 31st March, 2025.

Kindly take the same on your record.

For Jagadishwar Pharmaceutical Works Limited

Swapan



**Swapan Sarkar
Director**

DIN: 05149442